Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramipexole for restless legs syndrome in women with X-linked adrenoleukodystrophy
NL-OMON52216Phase 4Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of pramipexole in restless legs syndrome (RLS) (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: International Restless Legs Severity Scale total score, Suggested Immobilization Test leg movement activity and 1 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
pramipexole
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NL-OMON52216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52216.